| Description | Carbacyclin, a PGI2 analog, is a prostacyclin (PGI2) receptor agonist and vasodilator with potent inhibitory platelet aggregation. |
| In vitro | Carbacyclin acts as an inhibitor of platelet aggregation induced by ADP or collagen in vitro[2]. Carbacyclin activates CPT-1 mRNA expression through PPARδ, independent of the IP receptor signaling pathway. Carbacyclin (0.02 μM to 20 μM) activates the IP receptor signaling pathway via PKA, and such an effect is inhibited by H-89, a PKA inhibitor. Carbacyclin (0.02-80 μM) increases PPRE promoter activity via PPARδ independent of the IP receptor signaling pathway in cardiomyocytes [3]. |
| In vivo | Carbacyclin is 0.03 times as active as prostacyclin on inhibiting platelet aggregation in human, rabbit, or dog plasma [2]. In the murine heart, Carbacyclin (100 μg, i.p.) induces CPT-1 mRNA expression [3]. |
| Synonyms | Carbaprostacyclin, Carba-PGI2 |
| molecular weight | 350.49 |
| Molecular formula | C21H34O4 |
| CAS | 69552-46-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Takasuka M, et al. FTIR spectral study of intramolecular hydrogen bonding in thromboxane A2 receptor agonist (U-46619), prostaglandin (PG)E2, PGD2, PGF2 alpha, prostacyclin receptor agonist (carbacyclin), and their related compounds in dilute CCl4 solution: structure-activity relationships. J Med Chem. 1994 Jan 7;37(1):47-56. 2. Whittle BJ, et al. Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins. 1980 Apr;19(4):605-27. 3. Kuroda T, et al. Carbacyclin induces carnitine palmitoyltransferase-1 in cardiomyocytes via peroxisome proliferator-activated receptor (PPAR) delta independent of the IP receptor signaling pathway. J Mol Cell Cardiol. 2007 Jul;43(1):54-62. |